MolMed Adding $6.5M Ahead of Key Program Milestones
By Cormac Sheridan
Tuesday, January 22, 2013
With key regulatory and clinical events fast approaching, MolMed SpA is set to add about €5 million (US$6.5 million) to its balance sheet in a capital increase that is fully underwritten in all but name.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.